Biden selects Novo Nordisk’s GLP-1 drugs for Medicare price negotiation | The Health Management Academy

Solutions
Solutions for Health System
Solutions for Industry Innovators
- Executive Convening
- Data & Insights
In the Spotlight
Explore our convening solutions and join our vibrant community
Forums
Collaboratives
Insights
Topic Spotlight
Explore More Topics
Insights Memberships
The Health System CXO Podcast
A podcast on the key issues in healthcare, featuring innovators from across the industry.
In the Spotlight
Sign up today and get the latest news and insights from The Health Management Academy
Access the Academy 360 now
Subscribe to the Academy 360
Events
About Us
Our Mission
We power our members by building our community and fostering connections through executive peer learning. We support professional growth through talent and development. We accelerate understanding by delivering timely and actionable data and insights on key challenges. And we catalyze transformation by building alliances in areas where the power of the collective is greater than the power of one.
About Us
In the Spotlight
Find a career and team you love at The Health Management Academy
Explore Open Opportunities

insights
strategy catalyst
health policy and advocacy
biden selects novo nordisks glp 1 drugs for medicare price negotiation

Strategist | strategy-catalyst

Biden selects Novo Nordisk’s GLP-1 drugs for Medicare price negotiation

The Strategist lead image for web

Related Topics:

Health Policy and Advocacy

Relevant Roles:

Chief Strategy Officers

In one of his last official acts in office, President Biden selected semaglutide—the active ingredient in Novo Nordisk’s GLP-1 drugs Wegovy, Ozempic and Rybelsus—for Medicare drug price negotiations.